At the ESCMID Global 2025 conference, Bruker Corporation’s BRKR Microbiology and Infection Diagnostics division has announced the expansion of its microbiology solutions into Next-Generation ...

At the ESCMID Global 2025 conference, Bruker´s Microbiology and Infection Diagnostics division is announcing the expansion of ...

Bruker Corporation’s BRKR share price has dipped by 11.48%, which has investors questioning if this is right time to buy.

Bruker posts higher-than-expected Q1 revenue and announces NGS collaboration with Ridom to boost microbiology and infection ...

Barclays analyst Luke Sergott maintained a Buy rating on Bruker (BRKR – Research Report) today and set a price target of $50.00. The company’s ...

Bruker Corporation (Nasdaq: BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $800 million, comparing favorably to the Company’s ...

The company said, “This estimated range implies reported revenue growth of approximately 10% year-over-year, with low-double digit percentage ...

Bruker expects first-quarter revenue to be $795 million to $800 million, ahead of Wall Street expectations. Analysts polled by FactSet are forecasting $758.4 million in quarterly revenue. The ...

ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, ...

California Public Employees Retirement System cut its stake in shares of Bruker Co. (NASDAQ:BRKR – Free Report) by 9.8% in ...

Bruker Corporation BRKR has introduced an innovative Fourier 80 multinuclear benchtop FT-Nuclear Magnetic Resonance (NMR) spectrometer, known as the ‘Multi-Talent’ configuration. Unveiled at ...

Discover how Bruker’s BRAVO handheld Raman spectrometer is transforming material analysis with advanced fluorescence suppression and more.